OTC Drug Office Take Two: FDA To Elevate Division Through CDER Revamp
This article was originally published in The Tan Sheet
Executive Summary
A proposed reorganization of the Center for Drug Evaluation & Research Office of New Drugs would re-elevate the Division of OTC Drugs to office status
You may also be interested in...
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency
FDA Office Of Nonprescription Drugs To Assume Switch Management Duties
FDA's recently-christened Office of Nonprescription Drugs will take over project management responsibilities for Rx-to-OTC switches from the primary review division within the Center for Drug Evaluation & Research, according to the agency